These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 9208669)
21. [Initial management and adaptation of Parkinson's disease treatment]. Gérard JM Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969 [TBL] [Abstract][Full Text] [Related]
22. [Neuroprotective and neurorestorative therapy in Parkinson's disease]. Jiménez-Jiménez FJ; Molina JA Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687 [TBL] [Abstract][Full Text] [Related]
23. Use of apomorphine in Parkinson's disease. Stocchi F Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769 [TBL] [Abstract][Full Text] [Related]
24. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa. Okereke CS J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867 [TBL] [Abstract][Full Text] [Related]
25. Effective strategies in the management of Parkinson's disease. Wills AJ Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367 [TBL] [Abstract][Full Text] [Related]
27. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
28. [Parkinson disease and the neuronal dopamine uptake complex]. Costentin J Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268 [TBL] [Abstract][Full Text] [Related]
29. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
30. Mechanisms compensating for dopamine loss in early Parkinson disease. Brotchie J; Fitzer-Attas C Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312 [TBL] [Abstract][Full Text] [Related]
31. Recognition and treatment of response fluctuations in Parkinson's disease: review article. Verhagen Metman L Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528 [TBL] [Abstract][Full Text] [Related]
32. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon. Tse W J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614 [TBL] [Abstract][Full Text] [Related]
33. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Cools R Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475 [TBL] [Abstract][Full Text] [Related]
34. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946 [TBL] [Abstract][Full Text] [Related]
35. Motor fluctuations in Parkinson's disease. Weiner WJ Rev Neurol Dis; 2006; 3(3):101-8. PubMed ID: 17047575 [TBL] [Abstract][Full Text] [Related]
36. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Yamada K; Goto S; Hamasaki T; Kuratsu JI Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867 [TBL] [Abstract][Full Text] [Related]
37. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Encarnacion EV; Hauser RA Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609 [TBL] [Abstract][Full Text] [Related]
38. Modern treatment of Parkinson's disease. Pearce JM Br J Hosp Med; 1987 Jan; 37(1):59, 61, 64-6. PubMed ID: 3545340 [TBL] [Abstract][Full Text] [Related]